Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Phase 3
440
about 5.4 years
15–40
226 sites in AK, AL, AR +39
About this study
This trial is testing whether adding levocarnitine to standard chemotherapy protects the liver from damage caused by asparaginase, a drug used to treat leukemia and lymphoma. The goal is to see if levocarnitine can reduce severe liver toxicity in patients with ALL, LL, or MPAL.
Based on ClinicalTrials.gov records.
What participants do
- 1.Levocarnitine
- 2.Quality-of-Life Assessment
- 3.Take Calaspargase Pegol
- +2 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
calaspargase pegol, levocarnitine, pegaspargase
oral (Oral Capsule)
Secondary: Incidence of grade >= 3 alanine aminotransferase (ALT) or aspartate aminotransferase (AST) elevations during induction therapy
diagnostic
Oncology